Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Identify which bonds minimize taxes in retirement and why they work. This quick guide outlines tax-smart bond choices for retirees.
21,839 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Gallup's newest Life Evaluation Index shows more american workers struggling than thriving for the first time in the ...
As mortgage markets tighten and churn rises, lenders are turning to mentorship to convert recruits into steady, produ...
Jim Cramer asserts Five Below still has upside after a strong rally, driven by Winnie Park’s turnaround. The retailer...
Intel stock jumped about 8% after the company unveiled Core Ultra Series 3 enterprise processors on the 18A node and ...
Chewy just popped. stock momentum followed a better-than-expected 2026 outlook, even as Q4 growth stayed modest. This...
NVIDIA still leads the AI chip race, but investors are spreading bets downstream to adjacent AI opportunities as the ...
Barclays has boosted its Ionis target to $106, signaling a roughly 46% upside from recent levels as olezarsen eyes pe...
XRP exchange-traded funds booked their first monthly net outflow after a $1.2 billion rally, signaling a shift in inv...
Analysts issued fresh price targets on nine stocks, signaling divergent views as U.S. markets contend with rate uncer...
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Insider buying can hint at confidence from leadership, but it isn’t a crystal ball. This guide explains how to interp...